Barriers to HPV vaccine introduction and revitalization in sub-Saharan francophone African countries – A qualitative descriptive study

The pace of progress of HPV vaccine introduction in Sub-Saharan francophone African countries has been limited, particularly in conflict-affected countries. To better understand the barriers affecting the introduction and sustainability of the HPV vaccine, we conducted a qualitative study from January – April 2024 informed by insights from a multi-country HPV symposium. Our study explored […]

Pandemic-related resilience in HPV vaccination programmes – Perspectives from selected countries in Africa on what it will take to vaccinate 90% of girls by 2030

In this series of five country case studies, Kouassi and colleagues document how Côte d’Ivoire, Kenya, Liberia, Zambia, and Senegal maintained and recovered their HPV vaccination programmes following COVID-19 disruptions. Common challenges included school closures, misinformation conflating HPV and COVID-19 vaccines, and competing health priorities that diverted staff and funding. Enabling factors included strong Ministry […]

Routine HPV vaccination: Reflection on delivery strategies based on countries’ experiences

In this commentary, Waheed and colleagues reflect on HPV vaccine delivery strategies across several low- and middle-income countries, comparing country experiences against existing WHO guidelines. Three delivery approaches are documented: routinized campaign-mode vaccination using schools as the primary site (The Gambia, Zambia, Ethiopia), routine health facility services complemented by community and school outreach (Tanzania, Kenya, […]

Mobilisation des ressources et viabilité financière: Défis communs dans la préparation de la transition de Gavi – Côte d’Ivoire

En Côte d’Ivoire, la transition hors du financement de Gavi constitue l’un des défis programmatiques et financiers les plus structurants pour le programme national de vaccination. Bénéficiaire du soutien de Gavi depuis 2001, le pays est entré en phase de transition accélérée fin 2022, avec pour objectif un autofinancement complet d’ici 2030. Cette transition implique […]

Panorama situationnel du HPV – Côte d’Ivoire

Le programme de vaccination contre le HPV en Côte d’Ivoire, instauré au niveau national en 2019, s’appuie sur une collaboration multisectorielle impliquant le système éducatif et les leaders communautaires pour cibler les jeunes filles. Depuis août 2023, le pays a optimisé son protocole en adoptant un schéma vaccinal à dose unique pour les filles de […]

Formative insights to optimize the systematic medical visits, an integrated package of health services including HPV vaccination, in Côte d’Ivoire.

In Côte d’Ivoire, the national systematic medical visits (VMS) programme has integrated HPV vaccination since September 2023, combining it with multicomponent adolescent health services including screenings, nutrition assessments, and reproductive health counselling. Despite coverage gains, implementation remains uneven across delivery settings, with logistical gaps, limited intersectoral coordination, and inequitable cost distribution identified as key barriers […]

Resource Mobilization and Financial Sustainability: Common challenges in preparing for the Gavi transition – Cote d’Ivoire

In Côte d’Ivoire, the transition away from Gavi financing represents one of the most significant programmatic and financial challenges facing the national immunization programme. Having benefited from Gavi support since 2001, the country entered the accelerated transition phase in late 2022, with a target of full self-financing by 2030. This transition implies a more than […]

Country Snapshot – Côte d’Ivoire

Côte d’Ivoire’s HPV immunization landscape has evolved significantly since its national introduction in 2019, integrating vaccination into routine adolescent health packages and school medical check-ups. Following WHO recommendations, the program transitioned to a single-dose schedule in August 2023 for its primary target of 9-year-old girls, utilizing a quadrivalent vaccine delivered through fixed, mobile, and outreach […]

>